Programmable Medicine is a clinical stage company with a transformative nanomedicine technology exclusively licensed from Johns Hopkins University. The nanomedicine, hydroxyl dendrimers (HDs), precise ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN) is a biotechnology company leveraging, EpiSelect™, a proprietary discovery platform that enables precision targeting of disease causing epitopes on toxic misfo ...

Radiance Biopharma is developing next generation Antibody Drug Conjugates and Bispecific ADCs (BsADC)

RareSight is raising $2.5M Seed to reach product validation and a major inflection point within 18–24 months, with follow-on funding of approximately $7.5M supporting Phase I FIH studies through 50% c ...

Recall Therapeutics is pioneering a breakthrough platform for memory restoration in Alzheimer’s disease, with expansion into high-value indications across, oncology-related cachexia, and aging-associa ...

Receptive Bio is a Series A biotech advancing next-generation brain shuttles that leverages a novel BBB receptor and small-molecule binder to overcome key challenges of first-generation approaches and ...

RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products ...

As the leading healthcare communications agency since 1988, first as Noonan Russo and now Russo Partners, we have a unique understanding of our clients’ businesses.

A unique, unipotent autologous cell therapy for Alzheimer. Reversal of memory impairment & 9SD increase in synapses in AD dogs. No pluripotency or gene mods. Closed, automated, reliable CMC. Tier 1 st ...